针对纯合子家族性高胆固醇血症成人和儿童的低密度脂蛋白胆固醇降低疗法：挑战与成功 - Suppr

Suppr

超能文献

LDL-C-Lowering Therapies for Adults and Children With Homozygous Familial Hypercholesterolemia: Challenges and Successes.

作者信息

Santos Raul D, Cuchel Marina

机构信息

Lipid Clinic Heart Institute (InCor), University of Sao Paulo Medical School Hospital, Brazil (R.D.S.).

Academic Research Organization, Hospital Israelita Albert Einstein, Sao Paulo, Brazil (R.D.S.).

出版信息

Circulation. 2024 Jan 30;149(5):363-366. doi: 10.1161/CIRCULATIONAHA.123.067241. Epub 2024 Jan 29.

DOI:10.1161/CIRCULATIONAHA.123.067241

PMID:38285739

Abstract

摘要

相似文献

LDL-C-Lowering Therapies for Adults and Children With Homozygous Familial Hypercholesterolemia: Challenges and Successes.

Circulation. 2024 Jan 30;149(5):363-366. doi: 10.1161/CIRCULATIONAHA.123.067241. Epub 2024 Jan 29.

Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia.

Circulation. 2024 Jan 30;149(5):343-353. doi: 10.1161/CIRCULATIONAHA.123.065529. Epub 2023 Oct 20.

Gradual dose Titration of Lomitapide may Prevent Therapeutic Delays in Patients with Homozygous Familial Hypercholesterolemia.

J Atheroscler Thromb. 2023 Feb 1;30(2):203-205. doi: 10.5551/jat.LE003. Epub 2022 Jun 23.

The treatment of heterozygous familial hypercholesterolemia - a local perspective.

Endokrynol Pol. 2021;72(3):189-190. doi: 10.5603/EP.a2021.0055.

The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis.

Eur J Prev Cardiol. 2017 Nov;24(17):1843-1850. doi: 10.1177/2047487317730473. Epub 2017 Sep 19.

Evinacumab for Homozygous Familial Hypercholesterolemia.

N Engl J Med. 2020 Aug 20;383(8):711-720. doi: 10.1056/NEJMoa2004215.

Real-World Effectiveness of PCSK9 Inhibitors in Reducing LDL-C in Patients With Familial Hypercholesterolemia in Italy: A Retrospective Cohort Study Based on the AIFA Monitoring Registries.

J Am Heart Assoc. 2023 Nov 7;12(21):e026550. doi: 10.1161/JAHA.122.026550. Epub 2023 Oct 18.

Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia.

Vasc Health Risk Manag. 2012;8:651-9. doi: 10.2147/VHRM.S28581. Epub 2012 Nov 28.

Contemporary Homozygous Familial Hypercholesterolemia in the United States: Insights From the CASCADE FH Registry.

J Am Heart Assoc. 2023 May 2;12(9):e029175. doi: 10.1161/JAHA.122.029175. Epub 2023 Apr 29.

Homozygous familial hypercholesterolemia: the impact of novel treatments.

Eur J Prev Cardiol. 2024 Jun 3;31(8):1036-1037. doi: 10.1093/eurjpc/zwae094.

引用本文的文献

Evolving Concepts of the SCORE System: Subtracting Cholesterol from Risk Estimation: A Way for a Healthy Longevity?

Life (Basel). 2024 May 24;14(6):679. doi: 10.3390/life14060679.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

LDL-C-Lowering Therapies for Adults and Children With Homozygous Familial Hypercholesterolemia: Challenges and Successes.

作者信息

Santos Raul D, Cuchel Marina

机构信息

Lipid Clinic Heart Institute (InCor), University of Sao Paulo Medical School Hospital, Brazil (R.D.S.).

Academic Research Organization, Hospital Israelita Albert Einstein, Sao Paulo, Brazil (R.D.S.).

出版信息

Circulation. 2024 Jan 30;149(5):363-366. doi: 10.1161/CIRCULATIONAHA.123.067241. Epub 2024 Jan 29.

DOI:10.1161/CIRCULATIONAHA.123.067241

PMID:38285739

Abstract

摘要

相似文献

LDL-C-Lowering Therapies for Adults and Children With Homozygous Familial Hypercholesterolemia: Challenges and Successes.

Circulation. 2024 Jan 30;149(5):363-366. doi: 10.1161/CIRCULATIONAHA.123.067241. Epub 2024 Jan 29.

Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia.

Circulation. 2024 Jan 30;149(5):343-353. doi: 10.1161/CIRCULATIONAHA.123.065529. Epub 2023 Oct 20.

Gradual dose Titration of Lomitapide may Prevent Therapeutic Delays in Patients with Homozygous Familial Hypercholesterolemia.

J Atheroscler Thromb. 2023 Feb 1;30(2):203-205. doi: 10.5551/jat.LE003. Epub 2022 Jun 23.

The treatment of heterozygous familial hypercholesterolemia - a local perspective.

Endokrynol Pol. 2021;72(3):189-190. doi: 10.5603/EP.a2021.0055.

The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis.

Eur J Prev Cardiol. 2017 Nov;24(17):1843-1850. doi: 10.1177/2047487317730473. Epub 2017 Sep 19.

Evinacumab for Homozygous Familial Hypercholesterolemia.

N Engl J Med. 2020 Aug 20;383(8):711-720. doi: 10.1056/NEJMoa2004215.

Real-World Effectiveness of PCSK9 Inhibitors in Reducing LDL-C in Patients With Familial Hypercholesterolemia in Italy: A Retrospective Cohort Study Based on the AIFA Monitoring Registries.

J Am Heart Assoc. 2023 Nov 7;12(21):e026550. doi: 10.1161/JAHA.122.026550. Epub 2023 Oct 18.

Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia.

Vasc Health Risk Manag. 2012;8:651-9. doi: 10.2147/VHRM.S28581. Epub 2012 Nov 28.

Contemporary Homozygous Familial Hypercholesterolemia in the United States: Insights From the CASCADE FH Registry.

J Am Heart Assoc. 2023 May 2;12(9):e029175. doi: 10.1161/JAHA.122.029175. Epub 2023 Apr 29.

Homozygous familial hypercholesterolemia: the impact of novel treatments.

Eur J Prev Cardiol. 2024 Jun 3;31(8):1036-1037. doi: 10.1093/eurjpc/zwae094.

引用本文的文献

Evolving Concepts of the SCORE System: Subtracting Cholesterol from Risk Estimation: A Way for a Healthy Longevity?

Life (Basel). 2024 May 24;14(6):679. doi: 10.3390/life14060679.